蓝帆医疗
(002382)
| 流通市值：58.37亿 | | | 总市值：58.94亿 |
| 流通股本：9.98亿 | | | 总股本：10.08亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,705,296,598.46 | 1,624,785,065.65 | 5,739,692,552.6 | 4,181,728,803.56 |
| 营业收入 | 3,705,296,598.46 | 1,624,785,065.65 | 5,739,692,552.6 | 4,181,728,803.56 |
| 二、营业总成本 | 3,353,237,069.26 | 1,574,843,236.35 | 6,183,340,015.79 | 4,540,279,927.07 |
| 营业成本 | 2,604,032,597.21 | 1,218,310,039.38 | 4,840,417,326.36 | 3,610,323,665.65 |
| 税金及附加 | 28,107,045.4 | 13,155,832.15 | 52,260,542.11 | 39,027,857.89 |
| 销售费用 | 251,218,401.37 | 109,663,995.47 | 485,286,788.69 | 332,425,100 |
| 管理费用 | 162,150,646.63 | 78,074,969.68 | 329,495,541.6 | 226,080,232.83 |
| 研发费用 | 128,678,087.86 | 59,496,162.87 | 254,424,847.85 | 192,637,377.01 |
| 财务费用 | 179,050,290.79 | 96,142,236.8 | 221,454,969.18 | 139,785,693.69 |
| 其中:利息费用 | 116,304,807.45 | 69,481,704.35 | 272,065,572.26 | 205,741,051.68 |
| 其中:利息收入 | 12,490,252.78 | 7,658,254.93 | 24,720,606.73 | 20,255,835.07 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -81,570.72 | -50,272.53 | 497,722.83 | 6,606,212.02 |
| 加:投资收益 | -791,202.29 | -884,733.12 | 16,798,003.93 | 13,481,981.59 |
| 资产处置收益 | 107,698.92 | 119,941.05 | -1,649,674.87 | -411,420.42 |
| 资产减值损失(新) | -11,510,250.83 | 11,776,775.09 | -177,201,253.98 | -45,173,647.69 |
| 信用减值损失(新) | -23,613,240.07 | -7,430,752.64 | -21,050,566.63 | -8,068,920.4 |
| 其他收益 | 15,798,508.64 | 6,388,880.67 | 53,269,524.89 | 46,209,170.12 |
| 四、营业利润 | 331,969,472.85 | 59,861,667.82 | -572,983,707.02 | -345,907,748.29 |
| 加:营业外收入 | 9,275,515.08 | 7,160,382.45 | 20,162,897.9 | 2,442,771.57 |
| 减:营业外支出 | 5,473,339.68 | 936,277.95 | 108,314,730.91 | 4,225,285.77 |
| 五、利润总额 | 335,771,648.25 | 66,085,772.32 | -661,135,540.03 | -347,690,262.49 |
| 减:所得税费用 | 125,396,457.22 | 32,092,785.95 | 137,275,778.27 | -44,994,047.5 |
| 六、净利润 | 210,375,191.03 | 33,992,986.37 | -798,411,318.3 | -302,696,214.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 210,375,191.03 | 33,992,986.37 | -798,411,318.3 | -302,696,214.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 95,678,875.39 | 962,845.08 | -758,940,830.72 | -285,962,030.51 |
| 少数股东损益 | 114,696,315.64 | 33,030,141.29 | -39,470,487.58 | -16,734,184.48 |
| 扣除非经常损益后的净利润 | 79,722,820.86 | -9,496,791.42 | -833,961,001.83 | -364,366,368.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0 | -0.76 | -0.28 |
| (二)稀释每股收益 | 0.1 | 0 | -0.76 | -0.28 |
| 八、其他综合收益 | -167,150,636.29 | -91,161,983.42 | -69,235,627.82 | -12,376,023.67 |
| 归属于母公司股东的其他综合收益 | -139,049,482.81 | -76,247,253.93 | -59,926,504.86 | -8,952,690.58 |
| 九、综合收益总额 | 43,224,554.74 | -57,168,997.05 | -867,646,946.12 | -315,072,238.66 |
| 归属于母公司股东的综合收益总额 | -43,370,607.42 | -75,284,408.85 | -818,867,335.58 | -294,914,721.09 |
| 归属于少数股东的综合收益总额 | 86,595,162.16 | 18,115,411.8 | -48,779,610.54 | -20,157,517.57 |
| 公告日期 | 2026-08-25 | 2026-04-29 | 2026-04-29 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |